In the News
In the News
Cost Effectiveness of Topical Wound Oxygen Therapy for Chronic Diabetic Foot Ulcers
TWO2® therapy to be included in NHS supply chain framework agreement for 2025
AOTI’s Dr. Mike Griffiths on Breakthrough for Diabetic Foot Ulcers and Chronic Wound Care
AOTI Awarded Five Year Extension To Veterans Administration Contract
AOTI, INC. (the "Company" or "Group" or "AOTI") AOTI Awarded Five Year Extension To Veterans Administration Contract AOTI, INC., a medical technology group focused on the durable healing of wounds and prevention of amputations, is pleased to announce that it has been...
AOTI wins the Best Newcomer Award at the AIM Awards 2024
London Stock Exchange welcomes AOTI, Inc. celebrating its successful listing on AIM
AOTI announces US FDA 510(k) Clearance of NEXA™ NPWT system for use in the home care setting
AOTI, INC. (the “Company” or “Group” or “AOTI”) AOTI announces US FDA 510(k) Clearance of NEXA™ NPWT system for use in the home care setting Extension to Indications for Use follows submission of results from a human factors study evaluating the safe and effective use...
AOTI announces US FDA 510(k) Clearance of NEXA NPWT System for use in the home care setting
Treatment Recommendation for Diabetic Foot Ulcers (DFUs) by the Wound Healing Society
AOTI's at-home TWO2® therapy is able to deliver oxygen topically into chronic wounds, including Diabetic Foot Ulcers (DFUs), and to encourage high-quality, durable wound healing OCEANSIDE, Calif., Dec. 4, 2023 /PRNewswire/ -- AOTI Inc., the global leader in...